UNIVERSITY^{OF} BIRMINGHAM University of Birmingham Research at Birmingham

Impact of malnutrition on early outcomes after cancer surgery

GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery

DOI: 10.1016/S2214-109X(22)00550-2

License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery 2023, 'Impact of malnutrition on early outcomes after cancer surgery: an international, multicentre, prospective cohort study', *The Lancet Global Health*, vol. 11, no. 3, pp. e341-e349. https://doi.org/10.1016/S2214-109X(22)00550-2

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Articles

Impact of malnutrition on early outcomes after cancer surgery: an international, multicentre, prospective cohort study

GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery*

Summary

Background Malnutrition represents a key priority for global health policy, yet the impact of nutritional state on cancer surgery worldwide remains poorly described. We aimed to analyse the effect of malnutrition on early postoperative outcomes following elective surgery for colorectal or gastric cancer.

Methods We did an international, multicentre, prospective cohort study of patients undergoing elective surgery for colorectal or gastric cancer between April 1, 2018, and Jan 31, 2019. Patients were excluded if the primary pathology was benign, they presented with cancer recurrence, or if they underwent emergency surgery (within 72 h of hospital admission). Malnutrition was defined with the Global Leadership Initiative on Malnutrition criteria. The primary outcome was death or a major complication within 30 days of surgery. Multilevel logistic regression and a three-way mediation analysis were done to establish the relationship between country income group, nutritional status, and 30-day postoperative outcomes.

Findings This study included 5709 patients (4593 with colorectal cancer and 1116 with gastric cancer) from 381 hospitals in 75 countries. The mean age was $64 \cdot 8$ years (SD $13 \cdot 5$) and $2432 (42 \cdot 6\%)$ patients were female . Severe malnutrition was present in 1899 ($33 \cdot 3\%$) of 5709 patients, with a disproportionate burden in upper-middle-income countries ($504 [44 \cdot 4\%]$ of 1135) and low-income and lower-middle-income countries ($601 [62 \cdot 5\%]$ of 962). After adjustment for patient and hospital risk factors, severe malnutrition was associated with an increased risk of 30-day mortality across all country income groups (high income: adjusted odds ratio [aOR] $1 \cdot 96 [95\%$ CI $1 \cdot 14 - 3 \cdot 37$], p=0.015; upper-middle income: $3 \cdot 05 [1 \cdot 45 - 6 \cdot 42]$, p=0.003; low income and lower-middle income and lower-middle-income countries ($aOR 1 \cdot 41 = 55\%$ CI $1 \cdot 22 - 1 \cdot 64$]) and an estimated 40% of early deaths in upper-middle-income countries ($1 \cdot 18 [1 \cdot 08 - 1 \cdot 30]$).

Interpretation Severe malnutrition is common in patients undergoing surgery for gastrointestinal cancers and is a risk factor for 30-day mortality following elective surgery for colorectal or gastric cancer. There is an urgent need to examine whether perioperative nutritional interventions can improve early outcomes following gastrointestinal cancer surgery worldwide.

Funding National Institute for Health Research Global Health Research Unit.

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Introduction

Cancer surgery is a key global health issue, with the number of new cancer cases worldwide expected to reach 22.2 million in 2030.¹ Surgery is an integral part of cancer treatment, and the *Lancet Oncology* Commission on global cancer surgery estimated that 45 million procedures will be needed worldwide by 2030.² Patients with cancer commonly develop malnutrition, which has been linked to elevated all-cause mortality³ and worse postoperative outcomes.⁴ Patients undergoing surgery for cancer often present with loss of bodyweight, sarcopenia, and in some instances cachexia, all of which contribute to poor postoperative outcomes.⁵

A series published in 2020 highlighted that the double burden of malnutrition with the simultaneous presence of undernutrition and overnutrition is increasingly prevalent in low-income and middle-income countries (LMICs).⁶ This burden is likely to have been exacerbated by the COVID-19 pandemic causing delays in cancer diagnosis and subsequent presentation of patients with advanced-stage disease.⁷ Treating malnutrition in the perioperative period for at least 5 days has been shown to improve outcomes following cancer surgery⁸ and reduce hospital inpatient complications,^{9,10} and has been identified as an area of high research priority in LMICs.¹¹

To the best of our knowledge, there is a scarcity of high-quality data on the burden and impact of malnutrition in patients undergoing surgery for cancer worldwide. Retrospective study designs, small sample sizes, and the use of non-standardised malnutrition classification criteria restrict global comparisons. We aimed to analyse the effect of malnutrition on early





Lancet Glob Health 2023; 11: e341-49 See Comment page e302

*Investigators are listed at the end of the Article and appendix

Correspondence to: Professor Ewen M Harrison, NIHR Global Health Unit on Global Surgery, Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH16 4UX, UK ewen.harrison@ed.ac.uk

See Online for appendix

Research in context

Evidence before this study

Before undertaking the present study we searched for published multinational studies assessing the impact of malnutrition on early outcomes after surgery for gastrointestinal cancers, focusing on low-income and middle-income countries (LMICs). We searched PubMed, MEDLINE, Google Scholar, and ClinicalTrials.gov for studies published from inception to Oct 26, 2022, using the search terms "cancer" OR "malignancy" AND "surgery" AND "nutrition" OR "cachexia" AND "developing countries" OR "low income" OR "middle income" OR "low and middle income", without any language restrictions. Identified studies largely focused on single tumour types, were retrospective in nature, did not compare outcomes across multiple income settings, and often measured outcomes with non-standardised criteria. Preoperative nutrition has been identified as a research priority by surgical experts in LMICs.

Added value of this study

To the best of our knowledge, the present study is the first to provide comprehensive data across multiple income settings

postoperative outcomes in patients undergoing elective surgery for colorectal or gastric cancer.

Methods

Study design and participants

We did an international, multicentre, prospective cohort study of patients undergoing elective surgery for colorectal or gastric cancer. Predefined data items were collected according to a previously published protocol.¹² Investigators included consecutive patients undergoing surgery for breast, colorectal, and gastric cancer within 4-week time intervals between April 1, 2018, and Jan 31, 2019. Local investigators could select any 4-week interval within this period. Only patients with colorectal or gastric cancer were included in the present analysis because of the known high burden of malnutrition in patients with gastrointestinal cancer.³

Patients aged 18 years or older undergoing any procedure (laparoscopic, open, or robotic) requiring a skin incision under general or neuraxial anaesthesia were eligible for inclusion in this study. Patients undergoing purely diagnostic or staging procedures were excluded, as were patients undergoing surgical procedures for benign disease or cancer recurrence. Patients who underwent emergency surgery, defined as occurring within 72 h of hospital admission, were also excluded, as preoperative oral nutrition given for less than 3 days is often ineffective.¹³

Although the UK National Health Service (NHS) Research Ethics Committee considered this study exempt from formal research registration (South East Scotland Research Ethics Service, reference NR/161AB6), individual centres obtained their own audit or institutional approval on the impact of malnutrition on early outcomes in patients undergoing surgery for colorectal or gastric cancer. We prospectively collected data from 381 hospitals in 75 countries using standardised and validated methods. Severe malnutrition was common across all income groups. After case-mix adjustment, patients with severe malnutrition had higher rates of postoperative surgical-site infection and 30-day mortality than patients with no or moderate malnutrition. A third of the excess early mortality in LMICs following surgery was mediated by the presence of severe malnutrition.

Implications of all the available evidence

Malnutrition is disproportionately higher in LMICs than in high-income countries. Malnutrition contributes to significantly worse postoperative surgical-site infection and early mortality rates, with patients in LMICs experiencing additional morbidity and mortality risks. An urgent assessment of perioperative nutritional interventions led by in-country investigators is needed to evaluate the ability of these interventions to reduce early morbidity and mortality following surgery for cancer.

as appropriate. In participating hospitals in some countries, informed patient consent was taken orally or in writing, where required, whereas in other countries the requirement for patient consent was waived by local research ethics committees. This study was done in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.¹⁴

Data collection and validation

A summary of key patient and disease variables collected is provided in the appendix (p 1). Briefly, variables were selected to be objective, standardised, easily transcribed, and internationally relevant to maximise completeness and accuracy. Demographic variables such as age, sex, smoking, and comorbidities were identified on the basis of patient notes. Complications and death were confirmed through patient records at the 30-day follow-up, including any hospital notes or death certificates issued, or both. Nutritional status was defined with the Global Leadership Initiative on Malnutrition (GLIM) criteria,15 based on either BMI or percentage bodyweight loss within the preceding 6 months. Patients were defined as having severe malnutrition if they presented with a BMI less than 18.5 kg/m^2 or more than 10% unintentional bodyweight loss in 6 months.

Local investigators uploaded patient records to a secure online website through the Research Electronic Data Capture (REDCap) system.¹⁶ The lead investigator at each site checked the accuracy of all cases before submitting data. To ensure data quality, real-time assessment was done upon entry into the database and disparities were highlighted to local collaborators for

immediate review. The submitted data were then checked centrally, and when missing data were identified the local lead investigator was contacted and asked to complete the record. Online data visualisation tools aided this process. Records that remained incomplete were included in the patient flowchart but excluded from the analysis. Data were validated in three parts across a representative sample of centres according to a prespecified protocol. Case ascertainment and the accuracy of the collected data have previously been shown to be high.^v

Outcomes

The primary outcomes were postoperative mortality and a major complication within 30 days of surgery, as defined by Clavien–Dindo grade III, IV, or V.¹⁸ Death was included in the definition of major complication and therefore was not a competing risk. Secondary outcome measures were defined in the protocol¹² and included any 30-day complication (defined by Clavien-Dindo grade I–V), anastomotic leak, and surgical-site infection. Patients were assessed at 30 days to examine postoperative outcomes, with follow-up done in person, by telephone, or by review of medical records. In the event where 30-day follow-up records were unavailable, outcome status at the point of discharge from the hospital was recorded.

Statistical analysis

Scarce data meant that an a-priori sample size accounting for patient clustering was not possible. Variation across different international health settings was assessed by stratifying countries by World Bank country group classifications. Differences between country income groups were tested with the Pearson χ^2 test for categorical variables and the Kruskal-Wallis test for continuous variables.

Multilevel logistic regression models were constructed to account for case mix (differing patient, disease, and operative characteristics), with population stratification by hospital and country of residence incorporated as random intercepts with constrained gradients. An interaction term between country income group and nutritional state was included within each model to account for the potential co-linear relationship between malnutrition and World Bank tertile.¹⁹

Models were constructed with the following principles: confounders identified in previous studies were accounted for; demographic variables such as age and sex were included in model exploration; population stratification by hospital and country of residence was incorporated as random effects; all first-order interactions were checked and included in final models if found to be influential (reaching statistical significance, defined as p<0.05, or resulting in a \geq 10% change in the odds ratio of the explanatory variable of interest); and final model selection was done with a criterion-based approach by minimising the Akaike information criterion (AIC) and discrimination was determined with the C-statistic (area under the receiver operator curve). Effect estimates are presented as adjusted odds ratios (aORs) and 95% CIs. The variables included in the final models were World Bank income group, cancer type, age, sex, and disease stage.



Figure 1: Patient flowchart

<table-container>Vorde Bank incomeSila (74.0%)Sila (41.8%)Sila (26.3%)High incomeSila (16.6%)Sola (26.4%)Int3(19.4%)Low income or lower-Sila (9.4%)Sola (13.6%)Sola (13.6%)Indie incomeSila (9.4%)Sola (13.6%)Sola (13.6%)Cancer typeSila (13.6%)Sola (13.6%)Sola (13.6%)Goatric (stomach)Sjla (15.0%)Sola (26.6%)Sola (13.6%)Gastric (stomach)Sola (12.6%)Sola (13.6%)Sola (13.6%)Maen (SD)Go (14.2%)Sola (14.3%)Sola (14.6%)MaleSolo (57.9%)Sola (14.6%)3(13.6%)MaleSolo (57.9%)Sola (14.6%)3(13.6%)MissingSolo (14.6%)Sola (14.6%)Sola (14.6%)IISolo (14.6%)Sola (14.6%)Sola (14.6%)IISolo (14.6%)Sola (14.6%)Solo (14.6%)IISolo (14.6%)Sola (14.6%)Solo (14.6%)IISolo (14.6%)Sola (14.6%)Solo (14.6%)IISolo (14.6%)Sola (14.6%)Solo (14.6%)IISolo (14.6%)Solo (14.6%)Solo (14.6%)IISolo (14.6%)<th></th><th>Patients with no or moderate malnutrition</th><th>Patients with severe malnutrition</th><th>All patients</th></table-container>		Patients with no or moderate malnutrition	Patients with severe malnutrition	All patients					
High income2818 (74.0%)794 (41.8%)3612 (63.9%)Upper-middle income631 (16.6%)504 (26.4%)1.135 (19.9%)Low income or lower- middle income361 (9.4%)601 (31.6%)962 (16.8%)Jacter type53.1 (20.9%)1.356 (71.4%)4593 (80.5%)Cancer type53.1 (5.0%)54.3 (28.6%)1.116 (19.5%)Gastric (stomach)573 (15.0%)54.3 (28.6%)1.116 (19.5%)Jage, years54.2 (28.6%)62.6 (14.7%)64.8 (3.5%)Female1601 (42.0%)831 (43.7%)24.32 (42.6%)Male2206 (57.9%)1067 (56.2%)32.73 (57.3%)Male2206 (57.9%)1067 (56.2%)32.73 (57.3%)Male2020 (53.0%)968 (51.0%)29.88 (52.3%)II1051 (30.5%)53.6 (28.2%)1647 (29.7%)II1161 (30.5%)53.6 (28.2%)169 (29.7%)IV94 (2.5%)53.6 (28.3%)147 (2.6%)IV10.0%)60.3%)70.1%)IN35.0 (29.4%)120.6 (28.3%)147 (2.6%)IV10.0%)67.3 (53.6%)170.1(29.8%)IV10.0%67.5 (55.5%)170.1(29.8%)I1026 (26.9%)164.8 (58.9%)169.1(29.8%)I1026 (26.9%)164.8 (58.9%)169.1(29.8%)I122 (32.%)164.8 (58.9%)169.1(29.8%)I120.6 (26.9%)38.1 (24.7%)109.1(29.8%)I120.6 (27.9%)38.1 (24.7%)109.1(29.8%)I120.6 (26.9%)38.1 (24.7%) <t< td=""><td colspan="9">World Bank income group</td></t<>	World Bank income group								
lppper-middle income631 (16-6%)504 (26-4%)1335 (19-9%)low income or lower- middle income361 (9-4%)601 (31-6%)962 (16-8%)JCancer typeJ3237 (85-0%)1356 (71-4%)4593 (80-5%)Castric (stomach)573 (15-0%)543 (28-6%)1116 (19-5%)Gastric (stomach)573 (15-0%)543 (28-6%)1116 (19-5%)Jean (SD)65-8 (12-8)62-6 (14-7)64-8 (13-5)Fernale1601 (42-0%)831 (43-7%)2432 (42-6%)Male2206 (57-9%)1067 (56-2%)3273 (57-3%)Male2000 (53-0%)1067 (56-2%)3273 (57-3%)Male2020 (53-0%)1067 (56-2%)2988 (52-3%)Missing30 (1-1%)312 (16-4%)811 (14-1%)I499 (13-1%)312 (16-4%)811 (14-1%)I2020 (53-0%)968 (51-0%)2988 (52-3%)II1161 (30-5%)53 (2-8%)147 (2-6%)II101 (13-05%)53 (2-8%)147 (2-6%)V10 (0-9%)65 (2-9%)738 (38-9%)291 (0-1%)IV94 (2-5%)738 (38-9%)291 (2-2%)I02178 (57-2%)738 (38-9%)291 (2-2%)I11026 (26-9%)675 (35-5%)107 (2-9%)I2113 (15-8%)291 (2-2%)164 (8-6%)286 (5-0%)I3122 (32-2%)164 (8-6%)286 (5-0%)I11279 (33-6%)393 (2-7%)121 (21-2%)I2127 (21-3%)385 (22-3%)163 (30-9%)I3137 (8-62%)383 (High income	2818 (74·0%)	794 (41·8%)	3612 (63·3%)					
low income or lower- middle income361 (9.4%)601 (31-6%)962 (16.8%) Facer type 3237 (85.0%)3135 (71-4%)4593 (80.5%)Gastric (stomach)573 (15.0%)543 (28.6%)116 (19.5%) Age, years 555Mean (SD)65.8 (12.8)62.6 (14.7)64.8 (13.5) Female 1601 (42.0%)831 (43.7%)24.32 (42.6%)Male2026 (57.9%)1067 (56.2%)3273 (57.3%)Maising30.0.1%)10.01%)4 (0.1%)I2020 (53.0%)968 (51.0%)2988 (52.3%)II499 (13.1%)312 (16.4%)811 (14.1%)II2020 (53.0%)968 (51.0%)2988 (52.3%)III1161 (30.5%)536 (28.2%)169(79.9%)IV94 (2.5%)533 (28.3%)291 (93.1%)IV94 (2.5%)533 (28.3%)291 (93.1%)IV91 (10.0%)6 (0.3%)70 (13.9%)IV91 (20.2%)738 (38.9%)291 (51.1%)IV91 (20.2%)136 (36.9%)291 (93.1%)IV92 (12.3%)635 (12.3%)637 (12.2%)IV102 (32.6%)385 (20.3%)176 (30.9%)I1378 (36.2%)385 (20.3%)121 (21.2%)I1378 (36.2%)385 (20.3%)323 (30.	Upper-middle income	631 (16.6%)	504 (26.4%)	1135 (19·9%)					
Cancer typeColorectal (colon or rectum)3237 (85.0%)1356 (71.4%)4593 (80.5%)Gastric (stomach)573 (15.0%)543 (28.6%)1116 (19.5%)Age, years578 (12.8%)62.6 (14.7%)64.8 (13.5%)Mean (SD)65.8 (12.8%)62.6 (14.7%)64.8 (13.5%)Female1601 (42.0%)831 (43.7%)2432 (42.6%)Male2206 (57.9%)1067 (56.2%)3273 (57.3%)Missing30.01%)10.01%)4 (0.1%)Masore71067 (56.2%)3273 (57.3%)I499 (13.1%)312 (16.4%)811 (14.1%)I2020 (53.0%)968 (51.0%)2988 (52.3%)II1161 (30.5%)536 (28.2%)1697 (29.7%)II1161 (30.5%)536 (28.2%)1697 (29.7%)IV94 (2.5%)533 (28.3%)147 (26.6%)IV94 (2.5%)533 (28.3%)1697 (29.7%)IV94 (2.5%)533 (28.3%)1691 (29.6%)IV94 (2.5%)738 (38.9%)2916 (51.1%)IV1026 (26.9%)675 (35.5%)1701 (29.8%)I1026 (26.9%)675 (35.5%)1701 (29.8%)I1026 (26.9%)675 (35.5%)1901 (29.8%)I1026 (26.9%)675 (35.5%)1901 (29.8%)I1026 (26.9%)635 (29.3%)1963 (30.9%)I1026 (26.9%)635 (29.3%)1963 (30.9%)I1026 (26.9%)635 (29.3%)1963 (30.9%)I1378 (36.2%)385 (20.3%)1963 (30.9%)I </td <td>Low income or lower- middle income</td> <td>361 (9.4%)</td> <td>601 (31.6%)</td> <td>962 (16.8%)</td>	Low income or lower- middle income	361 (9.4%)	601 (31.6%)	962 (16.8%)					
Colorectal (colon or rectum)3237 (85·0%)1356 (71·4%)4593 (80·5%)Gastric (stomach)573 (15·0%)543 (28·6%)1116 (19·5%)Age, yearsMean (SD)65·8 (12·8)62·6 (14·7)64·8 (13·5)Sex </td <td>Cancer type</td> <td></td> <td></td> <td></td>	Cancer type								
Gastric (stomach)573 (15·0%)543 (28·6%)1116 (19·5%)Age, years62·6 (14·7)64·8 (13·5)Mean (SD)65·8 (12·8)62·6 (14·7)64·8 (13·5)Sex1724/32 (42·6%)Male2206 (57·9%)1067 (56·2%)3273 (57·3%)Male2206 (57·9%)1067 (56·2%)3273 (57·3%)Male2206 (57·9%)1067 (56·2%)3273 (57·3%)Masing3 (0·1%)1 (0·1%)4 (0·1%)I499 (13·1%)312 (16·4%)811 (14·1%)II2020 (53·0%)968 (51·0%)2988 (52·3%)III1161 (30·5%)536 (28·2%)1697 (29·7%)IV94 (2·5%)533 (2·8%)147 (2·6%)V10·0%)60·3%)7(0·1%)V94 (2·5%)533 (2·8%)1701 (2·8%)IV94 (2·5%)675 (35·5%)1701 (2·8%)V10·0%675 (35·5%)1701 (2·8%)I1026 (26·9%)675 (35·5%)1701 (2·8%)I1026 (26·9%)675 (35·5%)1701 (2·8%)I1026 (26·9%)164 (8·6%)286 (5·0%)I1026 (26·9%)385 (20·3%)1673 (3·9%)I1026 (26·9%)385 (20·3%)1701 (2·8%)I1026 (26·9%)385 (20·3%)1701 (2·8%)I1026 (26·9%)385 (20·3%)1701 (2·9%)I1026 (26·9%)385 (20·3%)1701 (2·9%)I1027 (3·3%)281 (2·3%)290 (3·6%)I1037 (8·3%)281 (2·3%)290 (3·6%)	Colorectal (colon or rectum)	3237 (85.0%)	1356 (71.4%)	4593 (80.5%)					
Age, yearsMean (SD) $65 \cdot 812 \cdot 8$) $62 \cdot 614 \cdot 7$) $64 \cdot 81 \cdot 31 \cdot 51$ Fernale $1601 (42 \cdot 00)$ $831 (43 \cdot 70)$ $243 \cdot 242 \cdot 63 \cdot 70$ Male $220 \cdot 65 \cdot 79 \cdot 90$ $1067 \cdot (56 \cdot 20)$ $3273 \cdot (57 \cdot 30)$ Male $220 \cdot 65 \cdot 79 \cdot 90$ $1067 \cdot (56 \cdot 20)$ $3273 \cdot (57 \cdot 30)$ Male $220 \cdot 65 \cdot 79 \cdot 90$ $1067 \cdot (56 \cdot 20)$ $3273 \cdot (57 \cdot 30)$ Masing $3 \cdot 01 \cdot 90$ $10 \cdot 10 \cdot 90$ $4 \cdot 01 \cdot 90$ I $499 \cdot (13 \cdot 10)$ $968 \cdot (51 \cdot 00)$ $2988 \cdot (52 \cdot 00)$ II $2020 \cdot (53 \cdot 00)$ $968 \cdot (51 \cdot 00)$ $1697 \cdot (29 \cdot 70)$ III $1161 \cdot (30 \cdot 50)$ $536 \cdot (28 \cdot 00)$ $1697 \cdot (29 \cdot 70)$ IV $94 \cdot (25 \cdot 50)$ $53 \cdot (28 \cdot 00)$ $147 \cdot (26 \cdot 60)$ V $10 \cdot 00 \cdot 90$ $60 \cdot 300$ $7 \cdot (01 \cdot 60)$ V $10 \cdot 00 \cdot 90$ $60 \cdot 300$ $7 \cdot (01 \cdot 60)$ V $10 \cdot 00 \cdot 90$ $241 \cdot 300$ $59 \cdot (09 \cdot 90)$ V $1026 \cdot (26 \cdot 90)$ $675 \cdot (35 \cdot 50)$ $1701 \cdot (29 \cdot 80)$ 1 $1026 \cdot (26 \cdot 90)$ $675 \cdot (35 \cdot 50)$ $1701 \cdot (29 \cdot 80)$ 2 $407 \cdot (10 \cdot 70)$ $290 \cdot (15 \cdot 30)$ $697 \cdot (12 \cdot 20)$ $10 \cdot 12 \cdot 21 \cdot 21 \cdot 21$ $100 \cdot 10 \cdot 100$ $100 \cdot 10 \cdot 100$ $10 \cdot 12 \cdot 21 \cdot 21 \cdot 21 \cdot 21 \cdot 21 \cdot 21 \cdot $	Gastric (stomach)	573 (15.0%)	543 (28.6%)	1116 (19.5%)					
Mean (SD) 65 8 (12.8) 62 6 (14.7) 64.8 (13.5) Sex Female 1601 (42.0%) 831 (43.7%) 2432 (42.6%) Male 2206 (57.9%) 1067 (56.2%) 3273 (57.3%) Missing 3 (0.1%) 1 (0.1%) 4 (0.1%) Formale 30.01%) 1 (0.1%) 811 (14.1%) I 499 (13.1%) 942 (16.4%) 811 (14.1%) II 2020 (53.0%) 968 (51.0%) 2988 (52.3%) III 1161 (30.5%) 536 (28.2%) 1697 (29.7%) IV 94 (2.5%) 533 (2.8%) 147 (2.6%) V 10.04% 6 (0.3%) 7 (0.1%) Missing 35 (0.9%) 24 (1.3%) 59 (0.9%) I 10.06 6 (7.3%) 1701 (29.8%) I 1026 (26.9%) 637 (35.5%) 1701 (29.8%) I 1026 (26.9%) 291 (3.1%) 291 (5.1%) I 1026 (26.9%) 385 (20.3%) 163 (30.9%) I 1026 (26.9%) 385 (20.3%)	Age, years								
SexFemale1601 (42.0%)831 (43.7%)2432 (42.6%)Male2206 (57.9%)1067 (56.2%)3273 (57.3%)Missing3 (0.1%)1 (0.1%)4 (0.1%) ASA score I499 (13.1%)312 (16.4%)811 (14.1%)II2020 (53.0%)968 (51.0%)2988 (52.3%)III1161 (30.5%)536 (28.2%)1697 (29.7%)IV94 (2.5%)536 (28.2%)1697 (29.7%)IV94 (2.5%)53 (2.8%)147 (2.6%)V10.0%6 (0.3%)7 (0.1%)Missing35 (0.9%)24 (1.3%)59 (0.9%)102178 (57.2%)738 (38.9%)2916 (51.1%)111026 (26.9%)675 (35.5%)1701 (29.8%)2407 (10.7%)290 (15.3%)697 (12.2%)3 or 4122 (3.2%)164 (8.6%)286 (50.0%)Missing77 (2.0%)32 (1.7%)109 (1.9%)II1378 (36.2%)385 (20.3%)1763 (30.9%)II1279 (33.6%)811 (42.7%)2090 (36.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)INising18 (0.4%)288 (15.2%)604 (10.6%)IV316 (8.3%)283 (12.2%)604 (10.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IV316 (8.3%)283 (12.2%)604 (10.6%)IV316 (8.3%)283 (1	Mean (SD)	65.8 (12.8)	62.6 (14.7)	64·8 (13·5)					
Female1601 (42·0%)831 (43·7%)2432 (42·6%)Male2206 (57·9%)1067 (56·2%)3273 (57·3%)Missing3 (0·1%)1 (0·1%)4 (0·1%)Missing3 (0·1%)1 (0·1%)4 (0·1%)ASacore2020 (53·0%)968 (51·0%)2988 (52·3%)II2020 (53·0%)968 (51·0%)2988 (52·3%)III1161 (30·5%)536 (28·2%)1697 (29·7%)IV94 (2·5%)536 (28·2%)1697 (29·7%)V10·0%6 (0·3%)7 (0·1%)Missing35 (0·9%)24 (1·3%)59 (0·9%)V10·0%6 (0·3%)7 (0·1%)Missing35 (0·9%)24 (1·3%)59 (0·9%)11026 (26·9%)738 (38·9%)2916 (51·1%)11026 (26·9%)675 (35·5%)1701 (29·8%)2407 (10·7%)290 (15·3%)697 (12·2%)3 or 4122 (3·2%)164 (8·6%)286 (5·0%)Missing77 (2·0%)32 (1·7%)109 (1·9%)II1378 (36·2%)385 (20·3%)1212 (21·2%)II1378 (36·2%)383 (20·3%)1212 (21·2%)III1279 (33·6%)288 (15·2%)604 (10·6%)Missing18 (0·4%)22 (1·1%)40 (0·7%)IV316 (8·3%)288 (15·2%)604 (10·6%)Missing18 (0·4%)286 (5·1%)1113 (58·6%)Missing2265 (59·4%)1113 (58·6%)3378 (59·2%)Missing2265 (59·4%)365 (19·2%)1216 (21·3%)Missing2265	Sex								
Male2206 (57·9%)1067 (56·2%)3273 (57·3%)Missing3 (0·1%)1 (0·1%)4 (0·1%)ASA scoreI499 (13·1%)312 (16·4%)811 (14·1%)II2020 (53·0%)968 (51·0%)2988 (52·3%)III1161 (30·5%)536 (28·2%)1697 (29·7%)IV94 (2·5%)533 (28·2%)147 (2·6%)V1 (0·0%)6 (0·3%)7 (0·1%)Missing35 (0·9%)24 (1·3%)59 (0·9%)CEOG performance stureI1026 (26·9%)675 (35·5%)1701 (29·8%)3 or 4122 (3·2%)164 (8·6%)286 (5·0%)Missing77 (2·0%)32 (1·7%)109 (1·9%)I1378 (36·2%)385 (20·3%)1212 (21·2%)II1378 (36·2%)383 (20·7%)1212 (21·2%)II1378 (36·2%)288 (15·2%)604 (10·6%)IV316 (8·3%)288 (15·2%)604 (10·6%)II1279 (33·6%)288 (15·2%)604 (10·6%)IV316 (8·3%)288 (15·2%)604 (10·6%)IV316 (8·3%)288 (15·2%)604 (10·6%)IV316 (8·3%)288 (15·2%)3378 (59·2%)II2265 (59·4%)113 (58·6%)3378 (59·2%)IV216 (21·3%)365 (19·2%)317 (16·7%)IV2265 (59·4%)313 (16·7%)3778 (13·6%)IV216 (21·3%)365 (19·2%)312 (21·3%)IV316 (8·3%)365 (19·2%)312 (21·3%)IV316 (8·	Female	1601 (42.0%)	831 (43·7%)	2432 (42.6%)					
Missing3 (0.1%)1 (0.1%)4 (0.1%)ASA scoreI499 (13.1%)312 (16.4%)811 (14.1%)II2020 (53.0%)968 (51.0%)2988 (52.3%)III1161 (30.5%)536 (28.2%)1697 (29.7%)IV94 (2.5%)533 (28.3%)147 (2.6%)V1 (0.0%)6 (0.3%)7 (0.1%)Missing35 (0.9%)24 (1.3%)59 (0.9%)D2178 (57.2%)738 (38.9%)2916 (51.1%)11026 (26.9%)675 (35.5%)1701 (29.8%)2407 (10.7%)290 (15.3%)697 (12.2%)3 or 4122 (3.2%)164 (8.6%)286 (5.0%)Missing77 (2.0%)32 (1.7%)109 (1.9%)Missing1378 (36.2%)385 (20.3%)1212 (21.2%)II1378 (36.2%)383 (20.7%)1212 (21.2%)II1279 (33.6%)811 (42.7%)2090 (36.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IV316 (8.3%)288 (15.2%)604 (10.6%)IN316 (8.3%)288 (15.2%)400 (7%)IV316 (8.3%)288 (15.2%)3378 (59.2%)IV316 (8.3%)365 (19.2%)3178 (59.2%)IV206 (55.9%4)1113 (58.6%)3378 (59.2%)IV206 (55.9%4)313 (16.7%)776 (13.6%)IV206 (55.9%4)317 (16.7%)776 (13.6%)IV206 (50.9%4)317 (16.7%)376 (13.6%)IV <td>Male</td> <td>2206 (57.9%)</td> <td>1067 (56·2%)</td> <td>3273 (57·3%)</td>	Male	2206 (57.9%)	1067 (56·2%)	3273 (57·3%)					
ASA score I 499 (13.1%) 312 (16.4%) 81.1 (14.1%) II 2020 (53.0%) 968 (51.0%) 2988 (52.3%) III 1161 (30.5%) 536 (28.2%) 1697 (29.7%) IV 94 (2.5%) 53 (2.8%) 147 (2.6%) V 1 (0.0%) 6 (0.3%) 7 (0.1%) Missing 35 (0.9%) 24 (1.3%) 59 (0.9%) EOGe performance start 50 (0.9%) 24 (1.3%) 59 (0.9%) 1 100.6% 6 (7.53.5%) 1701 (29.8%) 1 1026 (26.9%) 675 (35.5%) 1701 (29.8%) 2 407 (10.7%) 290 (15.3%) 697 (12.2%) 3 or 4 122 (3.2%) 164 (8.6%) 286 (5.0%) Missing 77 (2.0%) 32 (1.7%) 109 (1.9%) II 1378 (36.2%) 385 (20.3%) 1763 (30.9%) III 1378 (36.2%) 393 (20.7%) 1212 (21.2%) III 1279 (33.6%) 811 (42.7%) 2090 (36.6%) III 1279 (33.6%) 288 (15.2%)	Missing	3 (0.1%)	1(0.1%)	4 (0.1%)					
I 499 (13.1%) 312 (16.4%) 811 (14.1%) II 2020 (53.0%) 968 (51.0%) 2988 (52.3%) III 1161 (30.5%) 536 (28.2%) 1697 (29.7%) IV 94 (2.5%) 53 (2.8%) 147 (2.6%) V 1 (0.0%) 6 (0.3%) 7 (0.1%) Missing 35 (0.9%) 24 (1.3%) 59 (0.9%) ECOS performance stature 50 50.9%) 24 (1.3%) 59 (0.9%) I 10.06 (26.9%) 675 (35.5%) 1701 (29.8%) 1 1026 (26.9%) 632 (1.7%) 697 (12.2%) 3 or 4 122 (3.2%) 164 (8.6%) 286 (5.0%) Missing 77 (2.0%) 32 (1.7%) 109 (1.9%) II 1378 (36.2%) 385 (20.3%) 1763 (30.9%) II 1379 (33.6%) 288 (15.2%) 604 (10.6%) III 1279 (33.6%) 281 (42.7%) 2090 (36.6%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) III 1279 (33.6%) 288 (15.2%) 604 (10.6%) </td <td>ASA score</td> <td></td> <td></td> <td></td>	ASA score								
III 2020 (53·0%) 968 (51·0%) 2988 (52·3%) III 1161 (30·5%) 536 (28·2%) 1697 (29·7%) IV 94 (2·5%) 53 (2·8%) 147 (2·6%) V 1 (0·0%) 6 (0·3%) 7 (0·1%) Missing 35 (0·9%) 24 (1·3%) 59 (0·9%) ECOG performance stature 7 738 (38·9%) 2916 (51·1%) 1 1026 (26·9%) 675 (35·5%) 1701 (29·8%) 2 407 (10·7%) 290 (15·3%) 697 (12·2%) 3 or 4 122 (3·2%) 164 (8·6%) 286 (5·0%) Missing 77 (2·0%) 32 (1·7%) 109 (1·9%) II 1378 (36·2%) 385 (20·3%) 1763 (30·9%) II 1378 (36·2%) 393 (20·7%) 1212 (21·2%) III 1279 (33·6%) 811 (42·7%) 2090 (36·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) <	1	499 (13·1%)	312 (16·4%)	811 (14·1%)					
III 1161 (30-5%) 536 (28-2%) 1697 (29-7%) IV 94 (2-5%) 53 (2-8%) 147 (2-6%) V 1 (0-0%) 6 (0-3%) 7 (0-1%) Missing 35 (0-9%) 24 (1-3%) 59 (0-9%) ECOE performance 35 2178 (57-2%) 738 (38-9%) 2916 (51-1%) 1 1026 (26-9%) 675 (35-5%) 1701 (29-8%) 2 407 (10-7%) 290 (15-3%) 697 (12-2%) 3 or 4 122 (3-2%) 164 (8-6%) 286 (50-9%) Missing 77 (2-0%) 32 (1-7%) 109 (1-9%) Missing 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 1378 (36-2%) 393 (20-7%) 1212 (21-2%) II 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%)	Ш	2020 (53.0%)	968 (51.0%)	2988 (52·3%)					
IV 94 (2.5%) 53 (2.8%) 147 (2.6%) V 1 (0.0%) 6 (0.3%) 7 (0.1%) Missing 35 (0.9%) 24 (1.3%) 59 (0.9%) ECOC performance status 738 (38.9%) 29 (0.9%) I 1026 (26.9%) 675 (35.5%) 1701 (29.8%) 2 407 (10.7%) 290 (15.3%) 697 (12.2%) 3 or 4 122 (3.2%) 164 (8.6%) 286 (5.0%) Missing 77 (2.0%) 32 (1.7%) 109 (1.9%) Missing 1378 (36.2%) 385 (20.3%) 1763 (30.9%) II 1379 (33.6%) 811 (42.7%) 2090 (36.6%) IM 1279 (33.6%) 811 (42.7%) 2090 (36.6%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) IV 316 (8.3%) 285 (15.2%) 3037 (5.9.2%) Missing <td< td=""><td>Ш</td><td>1161 (30.5%)</td><td>536 (28.2%)</td><td>1697 (29.7%)</td></td<>	Ш	1161 (30.5%)	536 (28.2%)	1697 (29.7%)					
V 1 (0.0%) 6 (0.3%) 7 (0.1%) Missing 35 (0.9%) 24 (1.3%) 59 (0.9%) ECOC performance status 738 (38.9%) 2916 (51.1%) 0 2178 (57.2%) 738 (38.9%) 2916 (51.1%) 1 1026 (26.9%) 675 (35.5%) 1701 (29.8%) 2 407 (10.7%) 290 (15.3%) 697 (12.2%) 3 or 4 122 (3.2%) 164 (8.6%) 286 (5.0%) Missing 77 (2.0%) 32 (1.7%) 109 (1.9%) I 1378 (36.2%) 385 (20.3%) 1763 (30.9%) II 1378 (36.2%) 393 (20.7%) 1212 (21.2%) II 1378 (36.2%) 393 (20.7%) 1212 (21.2%) III 1279 (33.6%) 811 (42.7%) 2090 (36.6%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) Missing	IV	94 (2.5%)	53 (2.8%)	147 (2.6%)					
Missing 35 (0-9%) 24 (1-3%) 59 (0-9%) ECOG performance stature 738 (38-9%) 2916 (51-1%) 1 1026 (26-9%) 675 (35-5%) 1701 (29-8%) 2 407 (10-7%) 290 (15-3%) 697 (12-2%) 3 or 4 122 (3-2%) 164 (8-6%) 286 (5-0%) Missing 77 (2-0%) 32 (1-7%) 109 (1-9%) Encer stage 122 32-2%) 164 (8-6%) 286 (5-0%) I 1378 (36-2%) 32 (1-7%) 109 (1-9%) I 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 1378 (36-2%) 393 (20-7%) 1212 (21-2%) III 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 265 (59-4%) 1113 (58-6%) 3378 (59-2%)	V	1 (0.0%)	6 (0.3%)	7 (0.1%)					
ECOG performance status 0 2178 (57-2%) 738 (38-9%) 2916 (51-1%) 1 1026 (26-9%) 675 (35-5%) 1701 (29-8%) 2 407 (10-7%) 290 (15-3%) 697 (12-2%) 3 or 4 122 (3-2%) 164 (8-6%) 286 (5-0%) Missing 77 (2-0%) 32 (1-7%) 109 (1-9%) Cancer stage I 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 1378 (36-2%) 393 (20-7%) 1212 (21-2%) III 819 (21-5%) 393 (20-7%) 1212 (21-2%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Missing 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Gurrent smoker 459 (11-9%) 317 (16-7%) 776 (1	Missing	35 (0.9%)	24 (1.3%)	59 (0·9%)					
0 2178 (57·2%) 738 (38·9%) 2916 (51·1%) 1 1026 (26·9%) 675 (35·5%) 1701 (29·8%) 2 407 (10·7%) 290 (15·3%) 697 (12·2%) 3 or 4 122 (3·2%) 164 (8·6%) 286 (5·0%) Missing 77 (2·0%) 32 (1·7%) 109 (1-9%) Cancer stage 177 (2·0%) 32 (1·7%) 109 (1-9%) I 1378 (36·2%) 385 (20·3%) 1763 (30·9%) 1121 (21·2%) II 819 (21·5%) 393 (20·7%) 1212 (21·2%) III 1279 (33·6%) 811 (42·7%) 2090 (36·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) Missing 18 (0·4%) 22 (1·1%) 40 (0·7%) Missing 18 (0·4%) 22 (1·1%) 40 (0·7%) Missing 286 (5·9·4%) 1113 (58·6%) 3378 (59·2%) Never smoked 2265 (59·4%) 1113 (58·6%) 3378 (59·2%) Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Gurrent smoker<	ECOG performance sta	tus							
1 1026 (26·9%) 675 (35·5%) 1701 (29·8%) 2 407 (10·7%) 290 (15·3%) 697 (12·2%) 3 or 4 122 (3·2%) 164 (8·6%) 286 (5·0%) Missing 77 (2·0%) 32 (1·7%) 109 (1·9%) Cancer stage 177 (2·0%) 32 (1·7%) 109 (1·9%) I 1378 (36·2%) 385 (20·3%) 1763 (30·9%) II 819 (21·5%) 393 (20·7%) 1212 (21·2%) III 1279 (33·6%) 811 (42·7%) 2090 (36·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) Missing 18 (0·4%) 22 (1·1%) 40 (0·7%) Morer smoked 2265 (59·4%) 1113 (58·6%) 3378 (59·2%) Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Gurrent smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 604 (5·5%) 339 (5·9%)	0	2178 (57·2%)	738 (38-9%)	2916 (51·1%)					
2 407 (10.7%) 290 (15.3%) 697 (12.2%) 3 or 4 122 (3.2%) 164 (8.6%) 286 (5.0%) Missing 77 (2.0%) 32 (1.7%) 109 (1.9%) Cancer stage 1378 (36.2%) 385 (20.3%) 1763 (30.9%) I 1378 (36.2%) 393 (20.7%) 1212 (21.2%) II 819 (21.5%) 393 (20.7%) 1212 (21.2%) III 1279 (33.6%) 811 (42.7%) 2090 (36.6%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) Mever smoked 2265 (59.4%) 1113 (58.6%) 3378 (59.2%) Stopped >6 weeks ago 851 (22.3%) 365 (19.2%) 1216 (21.3%) Gurrent smoker 459 (11.9%) 317 (16.7%) 776 (13.6%) Missing 235 (6.2%) 640 (5.5%) 339 (5.9%)	1	1026 (26.9%)	675 (35·5%)	1701 (29.8%)					
3 or 4 122 (3·2%) 164 (8·6%) 286 (5·0%) Missing 77 (2·0%) 32 (1·7%) 109 (1·9%) Cancer stage I 1378 (36·2%) 385 (20·3%) 1763 (30·9%) II 819 (21·5%) 393 (20·7%) 1212 (21·2%) III 1279 (33·6%) 811 (42·7%) 2090 (36·6%) IV 316 (8·3%) 288 (15·2%) 604 (10·6%) Missing 18 (0·4%) 22 (1·1%) 40 (0·7%) Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Gurrent smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	2	407 (10.7%)	290 (15·3%)	697 (12·2%)					
Missing 77 (2.0%) 32 (1-7%) 109 (1-9%) Cancer stage I 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 819 (21-5%) 393 (20-7%) 1212 (21-2%) III 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 220 (1-1%) 40 (0-7%) Smoking status 3378 (59-2%) 500 (21-3%) Never smoked 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Gurrent smoker 459 (11-9%) 317 (16-7%) 776 (13-6%) Missing 235 (6-2%) 104 (5-5%) 339 (59-9%)	3 or 4	122 (3·2%)	164 (8.6%)	286 (5.0%)					
Cancer stage I 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 819 (21-5%) 393 (20-7%) 1212 (21-2%) III 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Smoking status 365 (19-2%) 1216 (21-3%) Never smoked 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Current smoker 459 (11-9%) 317 (16-7%) 776 (13-6%) Missing 235 (6-2%) 104 (5-5%) 339 (59-9%)	Missing	77 (2·0%)	32 (1.7%)	109 (1.9%)					
I 1378 (36-2%) 385 (20-3%) 1763 (30-9%) II 819 (21-5%) 393 (20-7%) 1212 (21-2%) III 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Smoking status 2 400 (0-7%) 1212 (21-3%) Never smoked 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Current smoker 459 (11-9%) 317 (16-7%) 776 (13-6%) Missing 235 (6-2%) 40 (5-5%) 339 (5-9%)	Cancer stage								
II 819 (21-5%) 393 (20-7%) 1212 (21-2%) III 1279 (33-6%) 811 (42-7%) 2090 (36-6%) IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Smoking status 2 21 (1-3%) 3378 (59-2%) Never smoked 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Current smoker 459 (11-9%) 317 (16-7%) 776 (13-6%) Missing 235 (6-2%) 140 (5-5%) 339 (59-9%)	I	1378 (36·2%)	385 (20.3%)	1763 (30.9%)					
III 1279 (33.6%) 811 (42.7%) 2090 (36.6%) IV 316 (8.3%) 288 (15.2%) 604 (10.6%) Missing 18 (0.4%) 22 (1.1%) 40 (0.7%) Smoking status 1113 (58.6%) 3378 (59.2%) Never smoked 2265 (59.4%) 1113 (58.6%) 3378 (59.2%) Stopped >6 weeks ago 851 (22.3%) 365 (19.2%) 1216 (21.3%) Current smoker 459 (11.9%) 317 (16.7%) 776 (13.6%) Missing 235 (6.2%) 104 (5.5%) 339 (5.9%)	Ш	819 (21·5%)	393 (20.7%)	1212 (21.2%)					
IV 316 (8-3%) 288 (15-2%) 604 (10-6%) Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Smoking status 1113 (58-6%) 3378 (59-2%) Never smoked 2265 (59-4%) 1113 (58-6%) 3378 (59-2%) Stopped >6 weeks ago 851 (22-3%) 365 (19-2%) 1216 (21-3%) Current smoker 459 (11-9%) 317 (16-7%) 776 (13-6%) Missing 235 (6-2%) 104 (5-5%) 339 (5-9%)	Ш	1279 (33·6%)	811 (42.7%)	2090 (36.6%)					
Missing 18 (0-4%) 22 (1-1%) 40 (0-7%) Smoking status 1113 (58.6%) 3378 (59.2%) Never smoked 2265 (59.4%) 1113 (58.6%) 3378 (59.2%) Stopped >6 weeks ago 851 (22.3%) 365 (19.2%) 1216 (21.3%) Current smoker 459 (11.9%) 317 (16.7%) 776 (13.6%) Missing 235 (6.2%) 104 (5-5%) 339 (5.9%)	IV	316 (8.3%)	288 (15.2%)	604 (10.6%)					
Smoking status Never smoked 2265 (59·4%) 1113 (58·6%) 3378 (59·2%) Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Current smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	Missing	18 (0.4%)	22 (1.1%)	40 (0.7%)					
Never smoked 2265 (59·4%) 1113 (58·6%) 3378 (59·2%) Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Current smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	Smoking status								
Stopped >6 weeks ago 851 (22·3%) 365 (19·2%) 1216 (21·3%) Current smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	Never smoked	2265 (59.4%)	1113 (58.6%)	3378 (59.2%)					
Current smoker 459 (11·9%) 317 (16·7%) 776 (13·6%) Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	Stopped >6 weeks ago	851 (22.3%)	365 (19-2%)	1216 (21.3%)					
Missing 235 (6·2%) 104 (5·5%) 339 (5·9%)	Current smoker	459 (11·9%)	317 (16.7%)	776 (13.6%)					
	Missing	235 (6.2%)	104 (5.5%)	339 (5.9%)					

The relationship between country income group and 30-day mortality was examined in a three-way decomposition of total effects into direct, indirect, and interactive effects. The mediator examined was nutritional status, defined as the presence or absence of severe malnutrition, with an exposure–mediator interaction term specified if informative. The model accounted for country income group and patient-level covariates, with uncertainty determined with bootstrap resampling (5000 draws) and 95% CIs constructed by use of percentiles.

	Patients with no or moderate malnutrition	Patients with severe malnutrition	All patients				
(Continued from previous column)							
Diabetes							
No	3071 (80.6%)	1501 (79.0%)	4572 (80.1%)				
Non-insulin dependent	545 (14·3%)	271 (14·3%)	816 (14.3%)				
Insulin	153 (4.0%)	83 (4.4%)	236 (4·1%)				
Missing	41 (1.1%)	44 (2·3%)	85 (1.5%)				
HIV status							
Negative	3799 (99.7%)	1897 (99.9%)	5696 (99.8%)				
Positive	10 (0.3%)	2 (0.1%)	12 (0.2%)				
Missing	1 (0.0%)	0 (0.0%)	1(0.0%)				
BMI							
Normal bodyweight (18·5–24·9 kg/m²)	1558 (40.9%)	954 (50·2%)	2512 (44.0%)				
Underweight (<18·5 kg/m²)	0 (0.0%)	307 (16·2%)	307 (5·4%)				
Overweight or obese (>24·9 kg/m²)	2252 (59·1%)	638 (33.6%)	2890 (50.6%)				
>10% bodyweight loss							
No	3810 (100.0%)	69 (3.6%)	3879 (67.9%)				
Yes	0 (0.0%)	1830 (96.4%)	1830 (32·1%)				
Data are n (%) or mean (SD). ASA=American Society of Anesthesiologists. ECOG=Eastern Cooperative Oncology Group.							

A sensitivity analysis based on multiple imputation with chained equations was done to account for missing values for all statistical models, under the missing at random assumption. Ten sets, each with ten iterations, were imputed with available patient-level explanatory variables according to the methodology described by Sterne and colleagues.²⁰ The outcome variable was included as a predictor but excluded from imputation, with Rubin's rules used to combine results.

All analyses were done with the R Foundation Statistical Program (version 4.1.1), with the finalfit, tidyverse, regmedint, and lme4 functions.

This study was prospectively registered with ClinicalTrials.gov (NCT03471494).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.

Results

5709 patients (4593 with colorectal cancer and 1116 with gastric cancer) from 381 hospitals in 75 countries were included (figure 1). Of all patients, 3612 (63·3%) were from high-income countries, 1135 (19·9%) were from upper-middle-income countries, and 962 (16·8%) were from low-income and lower-middle-income countries. Patient characteristics grouped by nutritional status are

www.thelancet.com/lancetgh Vol 11 March 2023

shown in the table, and patient characteristics grouped by country income group are shown in the appendix (p 3). Missingness of primary outcomes (30-day mortality and major complications) was similar across variables of interest (appendix p 5).

Severe malnutrition was common across all income groups. Overall, 1899 (33·3%) patients were severely malnourished at the time of their elective surgery, with a higher burden of severe malnutrition found in upper-middle-income (504 [44·4%] of 1135) and low-income and lower-middle-income (601 [62·5%] of 962) settings compared to high-income settings (794 [22·0%] of 3612). Severe malnutriton was more likely in patients from upper-middle-income (aOR 2·83 [95% CI 2·46–3·26]; p<0·0001) and low-income and lower-middle-income countries (aOR 5·91 [5·08–6·89]; p<0·0001; figure 2) than in patients from high-income countries. A further descriptive model is included in the appendix (p 8).

The distribution of unadjusted mortality and complications stratified by nutritional status across income group are shown in the appendix (pp 9-10). Severely malnourished patients had higher postoperative mortality than patients with no or moderate malnutrition across all income groups (high income: 25 [3.2%] of 784 vs 38 [1.4%] of 2804; upper-middle income: 19 [3.8%] of 497 vs eight [1.3%] of 624; low income and lowermiddle income: 45 [7.6%] of 591 vs ten [2.8%] of 358; appendix p 11). The proportion of patients who developed postoperative complications or surgical-site infection was higher in those with severe malnutrition than in those with no or moderate malnutrition, particularly in low-income and lower-middle-income countries. This association was similar across both colorectal and gastric cancer (appendix p 12). The distribution of unadjusted major complications (defined as Clavien-Dindo grade III or IV) across all postoperative outcomes is shown in the appendix (p 13).

Outcomes were adjusted in three-level models accounting for patient and disease factors nested within hospitals and country of treatment (figure 3; appendix pp 15-29). Severe malnutrition was associated with an increased risk of 30-day mortality across all income groups (high income: aOR 1.96 [95% CI 1.14-3.37], p=0.015; upper-middle income: 3.05 [1.45–6.42], p=0.003; low income and lower-middle income: 11.57[5.87-22.80], p<0.0001). In low-income and lowermiddle-income countries, patients with no or moderate malnutrition also had an increased risk of mortality at 30 days (aOR 4.47 [95% CI 1.81-11.03], p=0.001). A loss of more than 10% of a patient's bodyweight in the 6 months preceding their operation was associated with an increased risk of 30-day mortality (aOR 2.02 [95% CI 1·36-2·99], p=0·00053), as was being underweight (BMI <18.5 kg/m²) at the point of undergoing surgery (aOR 2.59 [95% CI 1.50-4.47], p=0.001; appendix p 30). Patients who were overweight appeared to have a lower risk of 30-day mortality, but this association was not

Odds ratio (95% Cl, log scale) p value World Bank income level (tertile) High Upper middle -- 2.83 (2.46-3.26) <0.0001</td> Low income and lower middle -- 5.91 (5.08-6.89) <0.0001</td>

Figure 2: Multivariable regression model for factors associated with presence of severe malnutrition

significant (aOR 0.80 [95% CI 0.54–1.18], p=0.26; appendix p 30).

The proportion of patients sustaining a major complication, any complication, or an anastomotic leak in adjusted analyses was similar across country income groups, except for potential evidence of fewer major complications in the absence of severe malnutrition in the upper-middle-income group (figure 4A–C). However, surgical-site infection was more likely to occur in patients with severe malnutrition in the upper-middle-income country group (aOR 2.30 [95% CI 1.46-3.62]; p=0.00035) and across all nutritional states in low-income and lower-middle-income country groups (no or moderate malnutrition: aOR 2.77 [95% CI 1.70-4.51]; p<0.0001; severe malnutriton: 3.00 [1.90-4.74]; p<0.0001;figure 4D). Similar associations were seen across colorectal and gastric cancer individually and in sensitivity analyses accounting for missing data (appendix pp 15-42).

The associations between country income group and 30-day mortality (figure 5A) and surgical-site infection (figure 5B) were examined in a three-way decomposition mediation model of nutritional status. A notable proportion of the excess mortality was mediated by severe malnutrition in upper-middle-income countries (aOR 1·18 [95% CI 1·08–1·30], 40%) and low-income and lower-middle-income countries (1·41 [1·22–1·64], 32%). Excess surgical-site infections were also mediated by severe malnutrition in upper-middle-income (aOR 1·04 [95% CI 1·01–1·07], 7%) and low-income and lower-middle-income (1·08 [1·02–1·15], 11%) countries. All effects persisted in a sensitivity analysis accounting for missing data (appendix pp 43–45).

Discussion

In this prospective study of patients undergoing cancer surgery from 381 hospitals in 75 countries, severe malnutrition was present across all income levels, with a disproportionate burden observed outside high-income settings. Severe malnutrition was associated with an increased risk of surgical-site infection and 30-day mortality, mediating around a third of early deaths following surgery for cancer. We noted additional morbidity and mortality even after adjustment for case mix, indicating that severe malnutrition imposed additional risks across all income groups, and particularly within LMICs. Provision of safe and equitable surgical care is increasingly recognised as an essential part of cancer care, while improving nutrition forms part of the UN Sustainable Development Goal 2.²¹ As delays in presentation are associated with poorer survival secondary to cancer cachexia,²² early cancer detection programmes and improved access to surgical care are likely to reduce preoperative malnutrition rates in LMICs. However, patients often present with malnutrition despite good access to cancer care services.²² Although malnutrition is associated with poorer outcomes, it represents a potentially modifiable risk factor to reduce the effects of cancer cachexia within the early postoperative period.²³ Meta-analyses of randomised controlled trials done in both high-income countries²⁴ and LMICs⁸ have shown that simple perioperative oral nutritional supplementation can reduce early morbidity and mortality, potentially representing a low-cost and sustainable intervention in LMICs to improve surgical outcomes.

The rates of severe malnutrition reported in our study were higher than previous estimates across LMICs for patients undergoing surgery for cancer.²⁵ For patients with severe malnutrition undergoing surgery, 30-day mortality was elevated across all income groups. We also found higher unadjusted postoperative complication rates in patients with severe malnutrition across all

		Odds ratio (95% CI, log scale)	p value
High income: no or moderate malnutrition			
Upper-middle income: no or moderate malnutrition		1.41 (0.57–3.47)	0.460
Low income and lower-middle income: no or moderate malnutrition		4.47 (1.81–11.03)	0.001
High income: severe malnutrition		1.96 (1.14–3.37)	0.015
Upper-middle income: severe malnutrition		3.05 (1.45-6.42)	0.003
Low income and lower-middle income: severe malnutrition	_	11.57 (5.87–22.80)	<0.0001
	0·5 1·0 2·0 5·0 10·0 15·0 20·0		



Α							В				
					Odds ratio (95% CI, log scale	p value)				Odds ratio (95% CI, log scale	p value)
High income: no or moderate malnutrition											
Upper-middle income: no or moderate malnutrition		•	—		0.54 (0.35–0.84)	0.006		-		0.89 (0.57–1.40)	0.623
Low income and lower-middle income: no or moderate malnutrition					1.42 (0.92–2.20)	0.114	_			1.23 (0.77–1.95)	0.388
High income: severe malnutrition					1.17 (0.92–1.47)	0.199				1.05 (0.88–1.25)	0.610
Upper-middle income: severe malnutrition			-	-	0.83 (0.55–1.25)	0.382			-	- 1.38 (0.88-2.15)	0.157
Low income and lower-middle income: severe malnutrition					1.51 (1.02–2.25)	0.041				- 1.42 (0.91-2.20)	0.122
	0.4	0.6	0.8 1.0	1.5 2.0	-		0.6 0.8	1.0	1.5 2.0)	
c							D				
High income: no or moderate malnutrition			,				Ļ				
Upper-middle income: no or moderate malnutrition	_		-		0.78 (0.43-1.41)	0.407				1.51 (0.95–2.40)	0.085
Low income and lower-middle income:					<u> </u>	0.291				2·77 (1·70-4·51)	<0.0001
High income: severe malnutrition					1.27 (0.90–1.79)	0.174		_		1.16 (0.90–1.50)	0.261
Upper-middle income: severe malnutrition					1.08 (0.62–1.90)	0.782				2.30 (1.46-3.62)	0.00035
Low income and lower-middle income: severe malnutrition					1.26 (0.72–2.21)	0.417				3.00 (1.90-4.74)	<0.0001
	0.4	0.6	0.8 1.0	1.5 2.0	_		0.9 1.0	1.5 2.0	3.0 4.0	⊤ 5·0	

Figure 4: Multilevel logistic regression-adjusted outcomes by World Bank country income group and nutritional status.

(A) Major postoperative complication. (B) All postoperative complications. (C) Anastomotic leak. (D) Surgical-site infection. All models were adjusted for World Bank income group, cancer type, age, sex, and disease stage.

www.thelancet.com/lancetgh Vol 11 March 2023

income groups. These differences disappeared after casemix adjustment in high-income countries but remained in LMICs. Increased postoperative complication rates have been previously reported in malnourished patients undergoing surgery within LMICs,²⁶ but the use of non-standardised outcome definitions has restricted interpretation of these findings.

Malnutrition reduces the physiological capacity to compensate for traumatic events, including major surgery,²⁶ with the negative impact of malnutrition on the anabolic process of wound healing and postoperative recovery well described.²⁷ Excess mortality in malnourished patients is likely to occur secondary to the inability to recover from the associated physiological stress associated with postoperative complications.²⁷ This finding highlights the importance of recognising nutritionally vulnerable patients early to allow additional support and escalation of care if appropriate.

Various nutritional assessment tools have been proposed to identify patients at increased risk of surgical complications, but these are often time consuming to complete.¹⁵ Despite high levels of awareness about the importance of nutritional assessment, few health-care providers routinely screen patients for malnutrition,²⁸ emphasising the need for simple and efficient assessment tools. In 2019, GLIM convened major clinical nutrition societies to reach a global consensus on the identification of criteria for the diagnosis of malnutrition in clinical settings.¹⁵

Our study provides evidence that GLIM criteria can be applied to a global patient cohort, and that this definition of malnutrition is associated with 30-day mortality and surgical-site infection following surgery for cancer. Furthermore, more than 10% bodyweight loss in 6 months and low BMI (<18.5 kg/m²), both diagnostic of cancer cachexia, were associated with 30-day mortality following cancer surgery in our cohort. This finding suggests that these criteria have potential as a simple preoperative screening tool to identify nutritionally vulnerable patients; however, further comparison with existing nutritional assessment tools in LMICs, such as the Malnutrition Universal Screening Tool and Subjective Global Assessment, is required to clarify the relative prognostic efficiency of GLIM criteria during routine use in the clinical setting.

A major strength of this study is its prospective design and use of standardised criteria to assess nutritional status and postoperative outcomes across multiple income settings. Data quality was ensured though collaborator-facing web applications and real-time data entry quality assurance, with independent validation verifying data accuracy and case ascertainment. Assessment of nutritional status and outcomes was standardised, and training was provided through an online platform. The quantification of surgical cancer care in resource-limited settings has been hindered by an insufficient amount of high-quality data. This study



Figure 5: Three-way decomposition mediation model of the association between country income group and 30-day mortality (A) and surgical-site infection (B), mediated by nutritional state

Model adjusted for patient, cancer, and disease covariates. Uncertainty determined with bootstrap resampling (5000 draws) and 95% CIs constructed with percentiles. OR=odds ratio.

therefore contributes to closing this knowledge gap and allows meaningful comparisons from multiple income settings following case-mix adjustment.

Our study has important limitations. We were only able to identify the presence of patients with severe malnutrition before surgery, using percentage bodyweight loss and a-priori categorised BMI, to ensure a high percentage of data completeness. Therefore, the comparison group contained both well-nourished patients and those with moderate malnutrition. As a result, our analysis is likely to have underestimated the true effect of severe malnutrition on postoperative outcomes. Meanwhile, we were unable to determine the mediation or additive effects of chronic malnutrition, which might be reflected by a low BMI at presentation. Bodyweight loss alone was a strong predictor of 30-day mortality, but further work is required to investigate the importance of chronic malnutrition to early postoperative outcomes following cancer surgery. Furthermore, for this analysis we used the phenotypic GLIM criteria and were unable to further stratify patients according to aetiological criteria, reduced food intake, and inflammatory markers.

We recognise that extending the follow-up period to 90 days would have allowed better capture of postoperative complications, since the impact of nutritional status was likely to persist beyond 30 days. However, the shorter 30-day follow-up period was chosen for pragmatic reasons to facilitate data completeness, particularly across resource-limited settings.

This prospective study did not include other globally prevalent cancers associated with malnutrition, such as gynaecological and oral cancer.³ To maximise case ascertainment and ensure data quality, a pragmatic decision was made to collect data on cancer types commonly treated across our collaborative network. Our results might therefore only be generalisable to patients presenting with colorectal or gastric cancer; additional studies are required to determine the impact of nutritional status on early postoperative outcomes globally for different cancers. We plan to explore this further in future work exploring early outcomes after surgery for breast cancer.

Additionally, we were not able to measure all relevant patient, disease, and hospital variables, and therefore residual confounding exists. In particular, differences in operative approach (minimally invasive versus open) were difficult to accommodate in analyses because many hospitals in LMICs cannot offer these minimally invasive procedures. Further studies assessing the benefits of these approaches will probably identify important opportunities for intervention. It will also be of interest to ascertain how surgical outcomes are influenced by the experience and expertise of surgeons; however, this analysis was beyond the scope of our study.

Finally, the combined impact of patient comorbidity on early postoperative outcomes following cancer surgery in this cohort remains uncertain. Preoperative comorbidity is known to correlate with poorer nutritional state, with potential confounding possible despite model adjustment for important patient and disease factors. However, the factors included in our model are likely to be co-linear with overall measures of patient comorbidity; furthermore, our results remained consistent across sensitivity analyses.

Severe malnutrition is common and associated with an increase in 30-day mortality and surgical-site infection rates following elective cancer surgery worldwide. This finding suggests that perioperative nutrition remains a promising and untapped target for future studies to determine which perioperative interventions can reduce mortality rates and prevent severe complications. If effective interventions are found, the identification and treatment of malnutrition perioperatively might represent a potential low-cost, sustainable intervention in LMICs to reduce postoperative mortality and complications. If research gaps are addressed, preoperative oral nutrition is likely to form part of future global surgical guidelines as a simple measure that can improve outcomes after surgery for cancer. An international pilot randomised controlled trial investigating the feasibility and effectiveness of a perioperative oral nutritional intervention delivered the week before elective cancer surgery is underway (NCT04448041).

In conclusion, severe malnutrition represents a high global burden in cancer surgery and is an independent risk factor for 30-day mortality and surgical-site infection following elective surgery for colorectal or gastric cancer worldwide. Perioperative nutritional interventions might improve outcomes after cancer surgery and are a promising area of future research, which should particularly focus on suitable oral interventions across all income settings.

GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery writing group

Aya M Riad, Stephen R Knight, Dhruv Ghosh, Pamela A Kingsley, Marie Carmela Lapitan, Marie Dione Parreno-Sacdalan, Sudha Sundar, Ahmad Uzair Qureshi, Apple P Valparaiso, Riinu Pius, Catherine A Shaw, Thomas M Drake, Lisa Norman, Adesoji O Ademuyiwa, Adewale O Adisa, Maria Lorena Aguilera, Sara W Al-Sagga, Ibrahim Al-Slaibi, Aneel Bhangu, Bruce M Biccard, Peter Brocklehurst, Sorrel Burden, Kathryn Chu, Ainhoa Costas-Chavarri, Anna J Dare, Muhammed Elhadi, Cameron J Fairfield, J Edward Fitzgerald, James Glasbey, Mark I van Berge Henegouwen, J C Allen Ingabire, T Peter Kingham, Ismaïl Lawani, Bettina Lieske, Richard Lilford, Laura Magill, Mayaba Maimbo, Janet Martin, Sonia Mathai, Kenneth A Mclean, Rachel Moore, Dion Morton, Dmitri Nepogodiev, John Norrie, Faustin Ntirenganya, Francesco Pata, Thomas Pinkney, Rajkumar Kottayasamy Seenivasagam, Antonio Ramos-De la Medina, Tracey E Roberts, Hosni Khairy Salem, Joana Simões, Richard J E Skipworth, Richard T Spence, Neil Smart, Stephen K Tabiri, Evropi Theodoratou, Hannah Thomas, Malcolm West, John Whitaker, Thomas G Weiser, Edwin Yenli, Ewen M Harrison,

Contributors

EMH, AOAde, AOAdi, JCAI, MLA, AB, BMB, PB, SB, AC-C, KC, AJD, TMD, CJF, JEF, DG, JG, IL, TPK, SRK, MCL, RL, LM, JM, DM, RM, DN, FN, JN, FP, TP, RP, AUQ, RKS, ARM, TER, MDP-S, HKS, CAS, JS, NS, RTS, SS, SKT, HT, APV, and TGW contributed to the study design. EMH, AOAde, JCAI, MLA, SWA-S, IA-S, AB, SB, KC, TMD, ME, CJF, JG, MivBH, SRK, MCL, BL, MM, RM, DN, RP, AUQ, RKS, ARM, MDP-S, HKS, CAS, JS, NS, RTS, SKT, TGW, and EY contributed to data collection. EMH, AOAde, AOAdi, JCAI, MLA, AB, SB, KC, TMD, ME, CJF, DG, JG, IL, SRK, SM, DN, FN, LN, RP, AUQ, ARM, AMR, CAS, JS, RJES, NS, RTS, SKT, and TGW contributed to data analysis. EMH, AOAde, AOAdi, JCAI, MLA, SWA-S, AB, SB, KC, TMD, ME, DG, JG, MivBH, IL, TPK, SRK, DN, LN, RP, RKS, ARM, AMR, CAS, JS, RJES, NS, RTS, SS, SKT, TGW, and MW contributed to data interpretation. EMH, AOAde, AOAdi, JCAI, MLA, SWA-S, IA-S, AB, BMB, PB, SB, AC-C, KC, AJD, TMD, ME, CJF, JEF, DG, JG, MIvBH, IL, TPK, PAK, SRK, MCL, BL, RL, LM, MM, JM, SM, KAM, DM, DN, FN, LN, JN, FP, TP, RP, AUQ, RKS, ARM, AMR, TER, MDP-S, CAS, JS, RJES, NS, RTS, SS, SKT, ET, HT, APV, TGW, MW, JW, and EY contributed to writing the manuscript. EMH, AMR, and SRK verified the data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors read and approved the final version of the manuscript.

Declaration of interests

AMR reports grant support from the Royal College of Surgeons (Intercalated Bachelor of Science in Surgery Award 2020). RJES reports grant support from NHS Research Scotland. MIvBH reports grant support from Stryker outside the submitted work; all fees were paid to their institution. PB reports grants and personal fees from the UK Medical Research Council, grants from the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and the Wellcome Trust, and personal fees from AG Biotest, outside the submitted work. TPK reports personal fees from Olympus Surgical outside the submitted work. ET declares grants from Cancer Research UK. TMD reports research funding from Aligos Therapeutics and Iterion Therapeutics for research unrelated to the submitted work. MDP-S reports personal fees from Abbott Laboratories, Fresenius Kabi, and Otsuka, outside the submitted work. NS reports personal fees from Gore and Medtronic, outside the submitted work. SS reports support from AOA Dx Industry, outside the submitted work. TGW reports support from Wellcome Leap, outside the submitted work. MW reports personal fees from Medtronic, outside the submitted work. All other authors declare no competing interests.

Data sharing

The dataset can be explored through an online visualisation tool. Hospital-level data can be shared by submitting an application via email to the corresponding author. For analyses of patient-level identifiable data within our trusted research environment, please email the corresponding author.

Acknowledgments

This study was funded by the NIHR Global Health Research Unit. ET is supported by a Cancer Research UK Career Development Fellowship (C31250/A22804). RJES is supported by NHS Research Scotland. The NIHR Global Health Research Unit Grant (NIHR 17-0799) funded hub development in a subset of contributing countries. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care.

References

- Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. *Lancet Oncol* 2012; 13: 790–801.
- 2 Sullivan R, Alatise OI, Anderson BO, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. *Lancet Oncol* 2015; 16: 1193–224.
- 3 Pressoir M, Desné S, Berchery D, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 2010; 102: 966–71.
- 4 Ho JWC, Wu AHW, Lee MWK, et al. Malnutrition risk predicts surgical outcomes in patients undergoing gastrointestinal operations: results of a prospective study. *Clin Nutr* 2015; 34: 679–84.
- 5 Shen Y, Hao Q, Zhou J, Dong B. The impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: a systematic review and meta-analysis. *BMC Geriatr* 2017; 17: 188.
- 6 Popkin BM, Corvalan C, Grummer-Strawn LM. Dynamics of the double burden of malnutrition and the changing nutrition reality. *Lancet* 2020; 395: 65–74.
- 7 Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol* 2020; 21: 1023–34.

- 8 Knight SR, Qureshi AU, Drake TM, et al. The impact of preoperative oral nutrition supplementation on outcomes in patients undergoing gastrointestinal surgery for cancer in low- and middle-income countries: a systematic review and meta-analysis. *Sci Rep* 2022; **12**: 12456.
- 9 Schuetz P, Fehr R, Baechli V, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. *Lancet* 2019; **393**: 2312–21.
- 10 Schuetz P, Seres D, Lobo DN, Gomes F, Kaegi-Braun N, Stanga Z. Management of disease-related malnutrition for patients being treated in hospital. *Lancet* 2021; **398**: 1927–38.
- Nepogodiev D, Moore R, Biccard B, et al. Prioritizing research for patients requiring surgery in low- and middle-income countries. *Br J Surg* 2019; 106: e113–20.
- 12 NIHR Global Health Research Unit on Global Surgery. Quality and outcomes in global cancer surgery: protocol for a multicentre, international, prospective cohort study (GlobalSurg 3). *BMJ Open* 2019; **9**: e026646.
- Miller KR, Wischmeyer PE, Taylor B, McClave SA. An evidencebased approach to perioperative nutrition support in the elective surgery patient. *JPEN J Parenter Enteral Nutr* 2013; 37 (suppl): 39S–50S.
- 14 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–49.
- 15 Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition — a consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10: 207–17.
- 16 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–81.
- 17 Knight SR, Shaw CA, Pius R, et al. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. *Lancet* 2021; 397: 387–97.
- 18 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–13.
- 19 WHO. More than one in three low- and middle-income countries face both extremes of malnutrition. Dec 16, 2019. https://www.who. int/news/item/16-12-2019-more-than-one-in-three-low--and-middleincome-countries-face-both-extremes-of-malnutrition (accessed Jan 5, 2023).
- 20 Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009; 338: b2393.
- 21 Meara JG, Hagander L, Leather AJM. Surgery and global health: a *Lancet* Commission. *Lancet* 2014; **383**: 12–13.
- 22 Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011; 12: 489–95.
- 23 Allison SP. Malnutrition, disease, and outcome. Nutrition 2000; 16: 590–93.
- 24 Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. *Cochrane Database Syst Rev* 2012; 11: CD008879.
- 25 Nakahara S, Nguyen DH, Bui AT, et al. Perioperative nutrition management as an important component of surgical capacity in lowand middle-income countries. *Trop Med Int Health* 2017; 22: 784–96.
- 26 Sungurtekin H, Sungurtekin U, Balci C, Zencir M, Erdem E. The influence of nutritional status on complications after major intraabdominal surgery. J Am Coll Nutr 2004; 23: 227–32.
- 27 Demling RH. Nutrition, anabolism, and the wound healing process: an overview. *Eplasty* 2009; 9: e9.
- 28 Rasmussen HH, Kondrup J, Ladefoged K, Staun M. Clinical nutrition in Danish hospitals: a questionnaire-based investigation among doctors and nurses. *Clin Nutr* 1999; 18: 153–58.

For the **online visualisation tool** see http://cancer.globalsurg.org